Chimeric Antigen Receptor T Cell Therapy and Its Significance in Multiple Myeloma

Area of Science:

• Hematologic Oncology
• Immunotherapy
• Cellular Therapy

Background:

• Multiple myeloma (MM) is a prevalent hematological malignancy with a significant global and US patient population.
• Current MM treatment involves combination therapies including chemotherapy, monoclonal antibodies, and immunomodulatory drugs.
• Chimeric antigen receptor (CAR) T cell therapy has emerged as a promising novel treatment strategy for MM.

Purpose of the Study:

• To review and highlight various tumor markers targeted for CAR T cell therapy in multiple myeloma.
• To discuss the mechanisms of action and potential adverse events associated with CAR T cell therapy in MM.

Main Methods:

• In vitro modification of patient-derived T cells to express chimeric antigen receptors targeting specific tumor antigens.
• In vivo administration of engineered CAR T cells to target and eliminate multiple myeloma cells.
• Review of literature on CAR T cell therapy targets and associated clinical outcomes and adverse events in MM.

Main Results:

• Identified target antigens for CAR T cell therapy in MM include BCMA, SLAMF7, CD38, CD138, CD19, immunoglobulin kappa light chain, and GPRC5D.
• CAR T cells exert anti-myeloma effects through cytolytic pathways, cytokine release, and the Fas/FasL axis.
• CAR T cell therapy demonstrates potential for improving survival and prognosis in multiple myeloma patients.

Conclusions:

• CAR T cell therapy offers a new avenue for treating multiple myeloma by targeting specific antigens.
• Despite promising efficacy, potential adverse events such as cytokine release syndrome, encephalopathy, and infections require careful management.
• Further research into optimizing CAR T cell therapy targets and mitigating adverse events is crucial for its broader clinical application in MM.